- Home
- PYPD vs OSTX Comparison
PYPD vs OSTX Comparison
Compare PYPD & OSTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- OSTX
- Stock Information
- Founded
- PYPD 2008
- OSTX 2018
- Country
- PYPD Israel
- OSTX United States
- Employees
- PYPD N/A
- OSTX N/A
- Industry
- PYPD Medical/Dental Instruments
- OSTX
- Sector
- PYPD Health Care
- OSTX
- Exchange
- PYPD Nasdaq
- OSTX NYSE
- Market Cap
- PYPD 36.0M
- OSTX 43.0M
- IPO Year
- PYPD 2020
- OSTX 2024
- Fundamental
- Price
- PYPD $3.50
- OSTX $1.83
- Analyst Decision
- PYPD Strong Buy
- OSTX Strong Buy
- Analyst Count
- PYPD 5
- OSTX 3
- Target Price
- PYPD $11.40
- OSTX $18.00
- AVG Volume (30 Days)
- PYPD 1.4M
- OSTX 756.1K
- Earning Date
- PYPD 08-13-2025
- OSTX 08-14-2025
- Dividend Yield
- PYPD N/A
- OSTX N/A
- EPS Growth
- PYPD N/A
- OSTX N/A
- EPS
- PYPD N/A
- OSTX N/A
- Revenue
- PYPD N/A
- OSTX N/A
- Revenue This Year
- PYPD N/A
- OSTX N/A
- Revenue Next Year
- PYPD N/A
- OSTX N/A
- P/E Ratio
- PYPD N/A
- OSTX N/A
- Revenue Growth
- PYPD N/A
- OSTX N/A
- 52 Week Low
- PYPD $2.30
- OSTX $1.12
- 52 Week High
- PYPD $4.42
- OSTX $7.00
- Technical
- Relative Strength Index (RSI)
- PYPD 56.01
- OSTX N/A
- Support Level
- PYPD $3.42
- OSTX N/A
- Resistance Level
- PYPD $3.62
- OSTX N/A
- Average True Range (ATR)
- PYPD 0.18
- OSTX 0.00
- MACD
- PYPD -0.03
- OSTX 0.00
- Stochastic Oscillator
- PYPD 60.51
- OSTX 0.00
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About OSTX OS THERAPIES INCORPORATED
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.